Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
66
Recruiting, any sponsor type, condition "bipolar"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed633
66 trials
Showing 1 to 25, recently updated first.
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderPivotal-lookingRecruiting
Alkermes, Inc.Industry
NCT05303064 · 220 participants (planned) · Start Jun 30, 2022 · Primary completion Dec 2027
Drug: OLZ/SAM; Olanzapine · For: Schizophrenia; Bipolar I Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Encino, California · 47 sites in all
Northumbria UniversityAcademic, hospital or other
NCT07750925 · 45 participants (planned) · Start Sep 21, 2026 · Primary completion Apr 30, 2028
Drug: Lithium carbonate (Priadel) · For: Healthy; Bipolar
Sites: Newcastle upon Tyne, United Kingdom
- A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06929273 · 450 participants (planned) · Start Jul 18, 2025 · Primary completion Jun 13, 2028
Drug: KarXT; Lithium and 2 more · For: Bipolar Disorder Type I With Mania
Sites: Glendale, Arizona; Scottsdale, Arizona; Tucson, Arizona · 191 sites in all
- A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.Pivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT04777357 · 338 participants (planned) · Start Apr 28, 2021 · Primary completion Mar 2027
Drug: Cariprazine; Placebo · For: Depression; Bipolar I Disorder
Sites: Bentonville, Arkansas; Anaheim, California; Beverly Hills, California · 87 sites in all
University of Sao PauloAcademic, hospital or other
NCT07472920 · 20 participants (planned) · Start Nov 12, 2026 · Primary completion Aug 2027
Drug: Empagliflozin (EMPA) · For: Bipolar Disorder; Bipolar Depression; Insulin Resistance
Sites: São Paulo, Brazil
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Pivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06951711 · 274 participants (planned) · Start Jun 13, 2025 · Primary completion Nov 2, 2026
Drug: KarXT · For: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Sites: Little Rock, Arkansas; Rogers, Arkansas; Culver City, California · 86 sites in all
- A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07286175 · 400 participants (planned) · Start Nov 24, 2025 · Primary completion Nov 2027
Drug: Brenipatide; Placebo · For: Bipolar Disorder
Sites: Orange, California; New Haven, Connecticut; Hialeah, Florida · 87 sites in all
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06229210 · 300 participants (planned) · Start Jan 25, 2024 · Primary completion Apr 28, 2032
Drug: Lumateperone · For: Schizophrenia; Bipolar Disorder; Autism Spectrum Disorder
Sites: Phoenix, Arizona; Little Rock, Arkansas; Anaheim, California · 65 sites in all
- Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric PatientsPivotal-lookingRecruiting
Intra-Cellular Therapies, Inc.Industry
NCT06372964 · 384 participants (planned) · Start May 14, 2024 · Primary completion Oct 31, 2031
Drug: Lumateperone; Placebo · For: Bipolar Depression
Sites: Dothan, Alabama; Little Rock, Arkansas; Anaheim, California · 68 sites in all
- A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotriginePivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07140913 · 424 participants (planned) · Start Oct 8, 2025 · Primary completion Jun 28, 2027
Drug: Xanomeline/Trospium Chloride; Placebo · For: Mania; Bipolar Disorder
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Bellflower, California · 109 sites in all
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
NCT06922318 · 50 participants (planned) · Start Aug 19, 2025 · Primary completion Aug 30, 2031
Drug: ZEN-3694; Testosterone cypionate and 2 more · For: Metastatic Castration-resistant Prostate Cancer
Sites: Baltimore, Maryland
- Lithium Versus Cariprazine in the Acute Phase Treatment of Bipolar Depression (DUAG9)Pivotal-lookingRecruiting
Aalborg University HospitalAcademic, hospital or other
NCT05913947 · 122 participants (planned) · Start Dec 13, 2022 · Primary completion Sep 1, 2028
Drug: Lithium; Cariprazine · For: Depression, Bipolar
Sites: Aalborg, Denmark
- HD-tDCS for Adolescent Bipolar Depression Targeting S1Pivotal-lookingRecruiting
Jiangsu Province Nanjing Brain HospitalAcademic, hospital or other
NCT07246044 · 100 participants (planned) · Start Oct 15, 2025 · Primary completion Dec 31, 2027
Drug: Antipsychotics, mood stabilizers, etc. · For: Adolescent; Bipolar Depression; tDCS and 2 more
Sites: Nanjing, China
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06951698 · 274 participants (planned) · Start Jun 11, 2025 · Primary completion Nov 1, 2026
Drug: KarXT · For: Bipolar-I Disorder With Mania or Mania With Mixed Features
Sites: Bentonville, Arkansas; Little Rock, Arkansas; Anaheim, California · 74 sites in all
China Medical University HospitalAcademic, hospital or other
NCT05977023 · 90 participants (planned) · Start Oct 4, 2023 · Primary completion Nov 2027
Drug: NMDAE; Placebo Cap · For: Bipolar I Disorder
Sites: Taichung, Taiwan
- Pramipexole vs Placebo Treatment in Bipolar Disorder With Anhedonic DepressionPivotal-lookingRecruiting
Daniel LindqvistAcademic, hospital or other
NCT07664852 · 126 participants (planned) · Start Oct 2026 · Primary completion Dec 31, 2029
Drug: Pramipexole; Placebo · For: Bipolar Disorder (BD)
Sites: Lund, Sweden
Bosnalijek D.DIndustry
NCT07858565 · 500 participants (planned) · Start Oct 30, 2025 · Primary completion Apr 2027
Drug: Quetiapine (drug); quetiapine + aripiprazole and 1 more · For: Schizophrenia; Bipolar Affective Disorder
Sites: Sarajevo, Bosnia and Herzegovina
- ALTO-100 in Bipolar Disorder With Depression (BD-D)Pivotal-lookingRecruiting
Alto NeuroscienceIndustry
NCT06656416 · 200 participants (planned) · Start Oct 2, 2024 · Primary completion Sep 2027
Drug: ALTO-100; Placebo · For: Bipolar Disorder I or II With a Major Depressive Episode
Sites: Birmingham, Alabama; Chandler, Arizona; Phoenix, Arizona · 68 sites in all
Vanda PharmaceuticalsIndustry
NCT05648591 · 100 participants (planned) · Start May 24, 2023 · Primary completion Dec 31, 2028
Drug: Iloperidone · For: Schizophrenia; Bipolar I Disorder
Sites: Dothan, Alabama; Little Rock, Arkansas; Denver, Colorado · 11 sites in all
- An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current ManiaPivotal-lookingRecruiting
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07288320 · 150 participants (planned) · Start Dec 24, 2025 · Primary completion Feb 2028
Drug: NBI-1117568; Placebo · For: Bipolar I Disorder; Mania
Sites: Little Rock, Arkansas; Cerritos, California; Garden Grove, California · 11 sites in all
National Institute of Mental Health (NIMH)NIH
NCT00025935 · 2,350 participants (planned) · Start Jan 1, 2002
Drug: Lithium · For: Mood Disorder
Sites: Bethesda, Maryland
Centre Hospitalier St AnneAcademic, hospital or other
NCT07741981 · 700 participants (planned) · Start Aug 20, 2026 · Primary completion Nov 1, 2036
Drug: Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales · For: Schizophrenia; Treatment Resistant Depression (TRD); Bipolar Disorder (BD) and 2 more
Sites: Paris, France
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07105111 · 100 participants (planned) · Start Aug 29, 2025 · Primary completion Jun 2028
Drug: Valbenazine · For: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder and 2 more
Sites: Bryant, Arkansas; Chino, California; Fresno, California · 19 sites in all
AbbVieAbbVie (ABBV)
NCT07071532 · 20 participants (planned) · Start Aug 20, 2026 · Primary completion Feb 2027
Drug: ABBV-932; Itraconazole · For: Bipolar Disorder
Sites: Los Alamitos, California; Grayslake, Illinois
- OSU6162 in Bipolar Depression (OBID)Recruiting
Göteborg UniversityAcademic, hospital or other
NCT05296356 · 22 participants (planned) · Start Oct 25, 2021 · Primary completion May 31, 2029
Drug: OSU6162 · For: Bipolar Depression
Sites: Gothenburg, Sweden
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.